Literature DB >> 9059133

New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation.

Y Shoenfeld1, I Krause, M Blank.   

Abstract

In this article we have presented our experiences and those of others with various experimental and novel treatments in an experimental model of murine SLE, induced by immunisation with pathogenic anti-DNA antibody (fig 4). Many of the treatments (summarised in the table) were highly effective in ameliorating clinical, serological, and histological manifestations of the disease. According to our results, it seems that hormonal treatments--such as testosterone metabolites, anti-oestrogens, or bromocriptine--as well as immunomodulation with IVIG or anti-CD4 antibodies, hold the most promising potential for application in lupus patients. We believe, therefore, that these types of treatment should receive high priority in human trials. It should be emphasised, however, that the timing of treatment may be critical, since several treatments were effective when used before or during the induction of the disease. This limitation may pose difficulty for human application, since the aetiology of SLE is still obscure and is probably multifactorial38; therefore it is not yet possible to identify patients at risk of developing SLE. Nevertheless, those treatments which proved to be effective might be used early in the course of the disease in lupus patients and hence influence the outcome of the disease, or may even induce partial or complete remission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059133      PMCID: PMC1752242          DOI: 10.1136/ard.56.1.5

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  65 in total

Review 1.  Insights into autoimmunity: from classical models to current perspectives.

Authors:  J C Gutierrez-Ramos; J L Andreu; I Moreno de Alboran; J Rodriguez; E Leonardo; G Kroemer; M A Marcos; C Martinez
Journal:  Immunol Rev       Date:  1990-12       Impact factor: 12.988

2.  Treatment of Systemic Lupus Erythematosus with Steroids: Report to The Medical Research Council by The Collagen Diseases and Hypersensitivity Panel.

Authors: 
Journal:  Br Med J       Date:  1961-10-07

3.  Danazol for Evan's syndrome due to SLE.

Authors:  P Aranegui; P Giner; M Lopez-Gomez; A el Amrani; J Jimenez-Alonso
Journal:  DICP       Date:  1990-06

4.  A suppressor T-lymphocyte cell line for autoimmune encephalomyelitis.

Authors:  K E Ellerman; J M Powers; S W Brostoff
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

5.  Induction of tolerance by monoclonal antibody therapy.

Authors:  R J Benjamin; H Waldmann
Journal:  Nature       Date:  1986 Apr 3-9       Impact factor: 49.962

6.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

7.  Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.

Authors:  R W McMurray; D Weidensaul; S H Allen; S E Walker
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

8.  Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies.

Authors:  S R Zhou; J N Whitaker
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

9.  Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.

Authors:  F Rossi; D R Jayne; C M Lockwood; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

10.  Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice.

Authors:  J R Roubinian; N Talal; J S Greenspan; J R Goodman; P K Siiteri
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Treatment options for juvenile-onset systemic lupus erythematosus.

Authors:  Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.